STAT3 and cardiovascular disorder: Patients with NAFLD usually have glucose metabolic disorders and insulin resistance, which not only increases the risk of impaired glucose tolerance, diabetes, or even cardiovascular disease, but also accelerates the progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis, and even liver cancer.22 Further, studies have shown that STAT3 activation can lead to insulin resistance and lipid metabolic disorders.12 Therefore, STAT3 might be a potentially important target for disorders associated with glucose and lipid metabolism.